JP2022504826A5 - - Google Patents

Info

Publication number
JP2022504826A5
JP2022504826A5 JP2021520222A JP2021520222A JP2022504826A5 JP 2022504826 A5 JP2022504826 A5 JP 2022504826A5 JP 2021520222 A JP2021520222 A JP 2021520222A JP 2021520222 A JP2021520222 A JP 2021520222A JP 2022504826 A5 JP2022504826 A5 JP 2022504826A5
Authority
JP
Japan
Prior art keywords
sequence
chain variable
variable domain
heavy chain
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021520222A
Other languages
English (en)
Japanese (ja)
Other versions
JP7596263B2 (ja
JP2022504826A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2019/051448 external-priority patent/WO2020073131A1/en
Publication of JP2022504826A publication Critical patent/JP2022504826A/ja
Publication of JP2022504826A5 publication Critical patent/JP2022504826A5/ja
Application granted granted Critical
Publication of JP7596263B2 publication Critical patent/JP7596263B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021520222A 2018-10-10 2019-10-10 4-1bb及び腫瘍関連抗原に結合する抗体構築物ならびにその使用 Active JP7596263B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862744059P 2018-10-10 2018-10-10
US62/744,059 2018-10-10
PCT/CA2019/051448 WO2020073131A1 (en) 2018-10-10 2019-10-10 Antibody constructs binding 4-1bb and tumor-associated antigens and uses thereof

Publications (3)

Publication Number Publication Date
JP2022504826A JP2022504826A (ja) 2022-01-13
JP2022504826A5 true JP2022504826A5 (cg-RX-API-DMAC7.html) 2022-10-18
JP7596263B2 JP7596263B2 (ja) 2024-12-09

Family

ID=70164178

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021520222A Active JP7596263B2 (ja) 2018-10-10 2019-10-10 4-1bb及び腫瘍関連抗原に結合する抗体構築物ならびにその使用

Country Status (10)

Country Link
US (1) US20230052369A1 (cg-RX-API-DMAC7.html)
EP (1) EP3864051A4 (cg-RX-API-DMAC7.html)
JP (1) JP7596263B2 (cg-RX-API-DMAC7.html)
KR (2) KR20260080511A (cg-RX-API-DMAC7.html)
CN (2) CN112996809A (cg-RX-API-DMAC7.html)
AU (1) AU2019356806B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021006784A2 (cg-RX-API-DMAC7.html)
CA (2) CA3113539A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021004058A (cg-RX-API-DMAC7.html)
WO (1) WO2020073131A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3146977A1 (en) * 2020-04-15 2021-10-21 Zymeworks Inc. Antibody constructs binding 4-1bb and folate receptor alpha and uses thereof
AU2021268340A1 (en) 2020-05-06 2022-12-08 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and CLEC12A
CN112794911B (zh) * 2021-04-14 2021-08-03 上海偌妥生物科技有限公司 人源化抗叶酸受体1抗体及其应用
AU2022260298A1 (en) * 2021-04-23 2023-11-02 Shanghai Henlius Biotech, Inc. Anti-gpc3 antibodies, multispecific antibodies and methods of use
CN116769041A (zh) * 2022-03-10 2023-09-19 合肥瀚科迈博生物技术有限公司 靶向msln和4-1bb的双特异性抗体及其应用
JP2025529310A (ja) * 2022-09-06 2025-09-04 ティージェイ バイオファーマ (シャンハイ) カンパニー, リミテッド 多特異性構築物およびその使用
KR20250089528A (ko) * 2022-10-18 2025-06-18 투불리스 게엠베하 신규한 napi2b 항체를 함유하는 신규한 항체 약물 접합체, 치료 방법 및 이의 용도
WO2025131027A1 (en) * 2023-12-21 2025-06-26 Lanova Medicines Development Co., Ltd. Anti-slc34a2/anti-4-1bb antibodies and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014509841A (ja) * 2011-01-18 2014-04-24 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 癌を治療するための組成物および方法
CN122399016A (zh) * 2014-03-15 2026-07-17 诺华股份有限公司 使用嵌合抗原受体治疗癌症
BR112018071612A2 (pt) * 2016-04-22 2019-02-19 Alligator Bioscience Ab polipeptídeos biespecíficos inovadores contra cd137
DK3529269T3 (da) * 2016-10-19 2026-02-23 Invenra Inc Antistof-konstruktioner
BR112019017628A2 (pt) * 2017-02-24 2020-07-07 Macrogenics, Inc. molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição

Similar Documents

Publication Publication Date Title
CN111518214B (zh) 靶向cldn18.2的双特异性抗体及其制备方法和应用
JP2019524693A5 (cg-RX-API-DMAC7.html)
JP6669722B2 (ja) Cd3結合ドメイン
TWI874613B (zh) 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法
US12098203B2 (en) Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSA
RU2018142544A (ru) Биспецифические связывающие белки и пути их применения
JP2020508655A5 (cg-RX-API-DMAC7.html)
JP2022545647A5 (cg-RX-API-DMAC7.html)
JP2019520797A5 (cg-RX-API-DMAC7.html)
JP2021515798A5 (cg-RX-API-DMAC7.html)
HRP20200390T1 (hr) Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma)
IL285101B2 (en) Antibodies targeting g-protein coupled receptor and methods of use
KR20180012860A (ko) 이종 이량체 다중 특이적 항체 포맷
JP2019502694A5 (cg-RX-API-DMAC7.html)
JP2023549537A5 (cg-RX-API-DMAC7.html)
IL274071B1 (en) Method for in vivo generation of multispecific antibodies from monospecific antibodies
JP2017504578A5 (cg-RX-API-DMAC7.html)
JP2013515508A5 (cg-RX-API-DMAC7.html)
JP2020502233A5 (cg-RX-API-DMAC7.html)
JP2018522888A5 (cg-RX-API-DMAC7.html)
JP2025508316A5 (cg-RX-API-DMAC7.html)
JP6966330B2 (ja) Iii型分泌装置標的化分子
CN116940598A (zh) 用于治疗表达cldn18.2的实体瘤的cldn18.2/cd3双特异性抗体
JP2017509323A5 (cg-RX-API-DMAC7.html)
JP2021511387A5 (cg-RX-API-DMAC7.html)